Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11419

Shown on this page

Current sort

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Fred Hutchinson Cancer Center

Live official records

Open in full search

Conditions: Nonalcoholic Steatohepatitis
Interventions: AZD2693, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 36
States / cities: Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 32 more

Conditions: Haemophilia A
Interventions: Denecimig; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Iowa City, Iowa • Metairie, Louisiana • Minneapolis, Minnesota + 15 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 176
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 39 more

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 27 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Claseprubart, Placebo; Drug
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
Interventions: CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Interventions: Zedoresertib, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas + 4 more

Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions: KPL-387, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more

Conditions: Atrial Fibrillation
Interventions: PKN605, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Tupelo, Mississippi • Camden, New Jersey • New York, New York + 3 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Clinical trials in Seattle, Washington

Filter and sort this location

Institutions in Seattle

Live official records

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis